Understanding the molecular biology of WIP1 inhibitors could increase the potency of WIP1 inhibitors in a specific subsets of tumors with PPM1D/RPS6KB1 and ERBB2 co-amplification that may lead to improved cancer care. This evidence concerns the gene ERBB2 and cancer.